This pharmaceutical company has already reviewed 12 varieties in 2022, and a total of 36 varieties have been selected in the first seven batches of centralized procurement

[Pharmaceutical Network Enterprise News] At present, the national procurement of drugs has been carried out to the seventh bat.
With the normalization of centralized procurement, the consistency evaluation of generic drugs has attracted more attention from pharmaceutical compani.
With continuous advancement, many pharmaceutical companies have received good ne.
Recently, the good news ofthe approval of Pemetrexed disodium for injection of Class 4 generic drugs of Kelun Pharmaceutical .
Pemetrexed disodium for injection is a metabolite with huge market spac.
After the variety was included in the 4+7 and expanded centralized procurement, the sales continued to grow rapidly, and the sales in 2019 were 5 billion yua.
According to data from Min.
com, the terminal market size of this product in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 4 billion yuan in 2021, reaching 4 billion yua.
With the approval of pemetrexed disodium for injection by Kelun Pharmaceutical, the number of domestic pharmaceutical companies with this variety has reached 2
In addition, some companies' listing applications are under review and approva.
However, from the perspective of the market structure, Eli Lilly has always occupied most of the market, which also means that the potential of domestic pharmaceutical companies is worth explorin.
In recent years, Kelun Pharmaceutical has actively promoted the consistency evaluation of generic drugs in order to gain a share of the fierce market competitio.
According to statistics, since 2022, Kelun Pharmaceuticals has accumulatively over-rated 12 varietie.
Among the 12 over-evaluated varieties, in addition to pemetrexed disodium for injection, ipratropium bromide solution for inhalation, sildenafil citrate orally disintegrating tablet, medium and long-chain fat emulsion are also regarded as over-evaluat.
/amino acid (16)/glucose (30%) injection, medium and long chain fatty emulsion/amino acid (16)/glucose (36%) injection, troglitatin succinate tablets, gadoterol injection and other products, and Medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection, medium and long chain fat emulsion/amino acid (16)/glucose (30%) injection, sildenafil citrate orally disintegrating tablets, e.
All varieties are the first to revi.
According to data from Min.

com, up to now, 82 varieties of Kelun Pharmaceutical have passed or are deemed to have passed the consistency evaluation, of which 34 have won the first over-evaluati.

Kelun Pharmaceutical actively participates in the national procurement of medicin.

Thanks to the continuous increase in the volume of generic drugs, Kelun Pharmaceutical, as one of the leading suppliers of national procurement, has won bids for 25 products in the past few rounds of national procureme.

In the seventh batch of centralized procurement that just announced the results not long ago, Kelun Pharmaceutical plans to win the bid for 11 varieties, including oseltamivir phosphate capsules, erlotinib hydrochloride tablets, afatinib maleate tablets and hydrochloric acid Many varieties such as Palonosetron Injection have not yet been listed for sale, and winning the bid will help drive further growth in performan.

What is more worth mentioning is that Palonosetron Hydrochloride Injection (used to prevent acute nausea and vomiting caused by chemotherapy) with a product specification of 5ml:075mg was just approved for production by Kelun Pharmaceuticals on June 28 this ye.

This time, the products have also entered the centralized procurement, which can be said to be on the bus in ti.

Up to now, Kelun Pharmaceutical has selected the first seven batches of 36 varieties and 52 specifications for centralized procureme.

Data shows that since the transformation in 2012, Kelun Pharmaceutical has launched more than 300 drug researches for domestic and foreign marke.

In the five-year period from 2017 to 2021, the company was approved to list 94 products
Among them, 33 products will be approved for listing in 2021, and another 30 products will be declared for producti.

It is foreseeable that with the surge in the number of more over-evaluated varieties, it is expected to help the company achieve outstanding results again in the future centralized procureme.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.